Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Pulike Biological Engineering's Net Margin % or its related term are showing as below:
SHSE:603566'
s Net Margin % Range Over the Past 10 Years
Min: 8.9 Med: 19.26 Max: 32.24
Current: 16.3
SHSE:603566's Net Margin % is ranked better than 85.24% of 942
companies
in the Biotechnology industry
Industry Median: -88.295
vs SHSE:603566: 16.30
Pulike Biological Engineering (SHSE:603566) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Pulike Biological Engineering Net Margin % Related Terms
Pulike Biological Engineering Net Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:603566 vs VRTX, REGN, ALNY: Net Margin % Comparison
For the Biotechnology subindustry, Pulike Biological Engineering's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pulike Biological Engineering Net Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Pulike Biological Engineering's Net Margin % distribution charts can be found below:
* The bar in red indicates where Pulike Biological Engineering's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pulike Biological Engineering (SHSE:603566) has a Net Margin % of 16.34% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Pulike Biological Engineering and its competitors. This is 15% below median its historical median of 19.26. Over the past decade, Pulike Biological Engineering's Net Margin % has ranged from 8.90 to 32.24. According to the industry distribution chart, Pulike Biological Engineering ranks #139 out of 942 companies in the Biotechnology industry, placing it in the top 14.8%.
Is Pulike Biological Engineering's Net Margin % too high?
Pulike Biological Engineering's current Net Margin % of 16.34% is 15% below median its 10-year median of 19.26. Over the past 10 years, this metric has ranged from a low of 8.90 to a high of 32.24. Based on the distribution chart, Pulike Biological Engineering ranks #139 out of 942 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Pulike Biological Engineering has a GF Score™ of 64/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Pulike Biological Engineering's Net Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Pulike Biological Engineering ranks #139 out of 942 companies for Net Margin %. This places Pulike Biological Engineering in the top 15% of its industry — outperforming the majority of peers. Historically, Pulike Biological Engineering's own Net Margin % has ranged from 8.90 to 32.24 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Pulike Biological Engineering and its competitors. Pulike Biological Engineering's current Net Margin % is 16.34%, which is 15% below median its own 10-year median of 19.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pulike Biological Engineering stock overvalued right now?
Based on GuruFocus' analysis, Pulike Biological Engineering (SHSE:603566) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥14.30, compared to a current price of ¥10.31 — trading 27.9% below its estimated fair value. The current Net Margin % is 16.34%, which is 15% below median its 10-year median of 19.26. Pulike Biological Engineering's overall GF Score™ is 64/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Pulike Biological Engineering (SHSE:603566), the current Net Margin % is 16.34% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pulike Biological Engineering (SHSE:603566) Overvalued in 2026?
Based on GuruFocus' analysis, Pulike Biological Engineering stock appears to be undervalued.
The current stock price of ¥10.31 is trading 27.9% below its estimated GF Value™ of ¥14.30.
GuruFocus considers Pulike Biological Engineering to be Modestly Undervalued.
Key valuation signals for SHSE:603566:
Net Margin %: 16.34% (15% below median its 10-year median of 19.26)
GF Value™: ¥14.30 vs. price of ¥10.31 (27.9% below fair value)
No single metric tells the full story. See the SHSE:603566 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pulike Biological Engineering Business Description
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:603566 has been successfully added to your 
